ｐ５３抗体，Ｃｙｃｌｉｎ　Ｄ１抗体を用いた声帯前癌病変の免疫組織化学的検討

DOI 被引用文献4件 参考文献20件

書誌事項

タイトル別名
  • Immunohistochemical Study of p53 and Cyclin D1 Proteins in Epithelial Dysplasia of the Vocal Cords.

この論文をさがす

抄録

The immunohistochemical expression of p53 and cyclin D1 proteins was evaluated in formalin-fixed, paraffin-embedded surgical specimens from 39 patients with epithelial hyperplasia and dysplasia of the vocal cords. The series for this study consisted of nine patients with hyperplasia, 12 with mild dysplasia, ten with moderate dysplasia, eight with severe dysplasia, eight with vocal cord polyps, and 14 with invasive squamous cell carcinoma (SCC). <BR>The following results were obtained. 1) The mean p53 positive rates were 0.81±0.37 (mean±STD%) in mild dysplasia, 5.56±1.18 in moderate dysplasia, 11.81±3.61 in severe dysplasia, and 39.23±12.78 in SCC. The p53 expression was negative in the polyp cases and mild dysplasia. 2) The mean cyclin D1 positive rates were 0.55±0.15 (mean±STD%) in hyperplasia, 5.16±1.53 in mild dysplasia, 8.02±5.25 in moderate dysplasia, 18.34±8.95 in severe dysplasia, and 32.20±17.77 in SCC. The cyclin D1 expression was negative in the polyp cases. <BR>In the cases of hyperplasia and dysplasia, the p53 and cyclin D1 positive rates increased significantly as the histological grade advanced (p <0.05). Some cases which recurred or progressed to cancer showed a significantly higher expression of p53 and cyclin D1 than the mean value for each lesion type. <BR>In the cases of SCC, there was no significant correlation between the p53 or cyclin D1 positive rates and either the degree of tumor cell differentiation or the T-classification. The p53 positive rates correlated with the cyclin D1 positive rates in all cases. <BR>These results suggest that a high expression of p53 and/or cyclin D1 may be associated with the recurrence and progression to malignancy in the precancerous lesions of the vocal cords seen in epithelial hyperplasia and dysplasia.

収録刊行物

被引用文献 (4)*注記

もっと見る

参考文献 (20)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ